

ONGOING KNOWLEDGE GAPS IN ANTIPLATELET THERAPY FOR HIGH-RISK DIABETES PATIENTS WITH CORONARY ARTERY DISEASE

Presented at the 2021 **American Diabetes Association Scientific** Sessions

Shpetim Karandrea, PhD; Neha Agarwal, PhD; Amanda Jamrogiewicz, CHCP; Cardiometabolic Health Congress, Boca Raton, FL

BACKGROUND

We sought to determine the impact of a live virtual CME activity on the knowledge and competence of multi-disciplinary clinicians about recent advances in antiplatelet therapy for diabetes patients with CAD.

METHODS

PRE-ACTIVITY **SURVEY**

Knowledge & Competence



LIVE VIRTUAL PRIMETIME SYMPOSIUM

with patient cases and expert discussions



POST-ACTIVITY SURVEY

Knowledge, Competence, Barriers to Best Practice, Intended Changes




2020 CMHC Annual Meeting, October 2020

RESULTS


LEARNER DEMOGRAPHICS

263 Learners **107** Certificates


DEGREE BREAKDOWN




SPECIALTY BREAKDOWN




IMPACT ON KNOWLEDGE & COMPETENCE





INTENDED PRACTICE CHANGES



Consider the use of more potent antiplatelet therapy for the prevention of adverse CVD events in high-risk cardiometabolic patients with CAD


49%

Recommend antithrombotic and antiplatelet therapy for high-risk type 2 diabetes patients according to current evidence and guidelines

60%


Assess patients with type 2 diabetes for risk of primary or recurrent thrombotic adverse events and balance ischemic risk vs. bleeding risk to optimize outcomes

ONGOING EDUCATIONAL GAPS



treatment

Failure to recognize how diabetes can impact CAD



Continued unawareness about novel approaches to CAD management in patients with type 2 diabetes

Failure to correctly individualize CAD therapy in high-risk diabetes patients

CONCLUSIONS

The study demonstrated ongoing knowledge and competence gaps among multi-disciplinary clinicians that see high-risk diabetes patients about the optimization of antiplatelet therapy in this setting, as well as recent advances in antiplatelet therapy.

ACKNOWLEDGEMENTS & RESOURCES

This activity was jointly provided by the Cardiometabolic Health Congress and Postgraduate Institute for Medicine

Supported by an independent educational grant from AstraZeneca



DISCLOSURES

The authors report no conflicts of interest as it relates to this presentation